How Biotech Companies Stay Competitive With M&A Strategies

Laden...

2 jaren geleden

Html
Tekst

This week's Fierce Pharma Marketing is brought to you by AlphaSense.

Deal or No Deal: How Biotech Companies Stay Competitive With M&A Strategies

Thursday, April 21, 2022 | 11am ET / 8am PT

While there is no shortage of innovation in biotech, there are still major challenges faced by all companies. Within the evolving drug development landscape, it’s no surprise that external innovation through partnerships and acquisitions is a critical part of the biotech ecosystem. We are thrilled to have Dr. Yaron Werber join us to share a behind-the-scenes look at what goes on before and after deals reach the negotiating table.

You’ll walk away with:

An overview of the biggest M&A trends and forecasts in the biotech space The ingredients for a successful deal from both the perspective of the acquirer and smaller companies How to evaluate when to take a risk, and the different challenges between internal and external innovation.

You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce Life Sciences, simply unsubscribe.
Refer to our Privacy Policy.
Fierce Life Sciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2021 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission.

Deel deze op

Laden...

Andere nieuwsbrieven van Fiercebiotech.com

Meer nieuwsbrieven van Fiercebiotech.com

Laden...

How Biotech Companies Stay Competitive With M&A Strategies

Deel deze op

Andere nieuwsbrieven van Fiercebiotech.com

Gerelateerde nieuwsbrieven